Clinical Trials Browser

Phase 2 × Osilodrostat × 1 year × Clear all

NCT07104812 2026-02-11

Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)

Phase 2 Recruiting

ACTH Syndrome, Ectopic, Adrenal Hyperplasia, Congenital, Cushing Syndrome